Rotavirus P [4] (1) . In a community with reported vaccination coverage of 50%, the P [4] G2 strain was detected in all 21 rotavirus-positive stool samples identi? ed during November 2006-February 2007. Although monitoring effectiveness of Rotarix against P [4] G2 strains is of interest (2) , the small sample size, short duration of surveillance, and lack of a comparison group preclude ? rm assessment of an association between P[4]G2 predominance and vaccination.
Because Rotarix was introduced in Brazil in March 2006, most children >12 months old (66 [51%] of 129) in the study were ineligible for vaccination. Genotype P [4] G2 was the only strain identi? ed even in older children, which suggests either a change in disease ecology from vaccination or the random circulation of P [4] G2 strains in the community. Ongoing hospitalbased surveillance during 2006 in 3 regional countries that had not introduced rotavirus vaccine (El Salvador, Guatemala, and Honduras) showed that P [4] G2 was the predominant circulating strain (prevalence 68%-81%). Thus, as previously documented (3, 4) , the predominance of P [4] G2 strains after Rotarix introduction in Brazil could represent a natural shift unrelated to vaccination.
Evaluation of vaccine effectiveness against speci? c strains will allow full assessment of the public health impact of vaccination. Although the data are sparse in the study from Gurgel et al., a comparison of the odds of vaccination among rotavirus-positive (cases) versus rotavirus-negative (controls) children shows 80% vaccine effectiveness against P [4] 
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LETTERS
To the Editor: Gurgel et al. described the predominance of P [4] G2 rotaviruses in a vaccinated population in Aracaju, northeastern Brazil (1). However, several limitations need to be addressed to avoid misinterpretation of data that could lead to loss of con? dence in the vaccine in Brazil and other countries.
Brazil was one of the ? rst countries in Latin America to introduce a live, oral, attenuated human rotavirus vaccine into a public-sector health program. Nevertheless, vaccine coverage levels vary considerably across regions (≈40% to >80%) and are ≈50% in some parts of northern and northeastern Brazil. Therefore, drawing conclusions about the vaccine's protection and prevailing rotavirus genotypes in a setting where coverage is still low seems premature.
Two ? ndings require special consideration. First, although the number of patients is small, children <1 year of age showed a reduced risk for severe rotavirus diarrhea among vaccinated (7%) patients compared with nonvaccinated (26%) patients: p<0.05; odds ratio (OR) 0.20; exact 95% con? dence interval (CI) 0.029-1.24. Second, surveillance was conducted for only 4 months, which did not allow for demonstration of a true representative pattern of strain distribution over time. The sequential changing predominance of rotavirus serotypes occurring over time has been well documented for many years (2) .
The authors stated that the "vaccine does not afford complete protection against infection" (1). For those not paying close attention to data analysis, this statement could be misinterpreted to mean that the vaccine may not protect against P [4] G2. To the contrary, even with a small sample size and low vaccine coverage, additional analyses of the original data show that the live, oral, attenuated human rotavirus vaccine can protect against the 100% predominance of P [4] G2.
In a large phase III trial conducted in Latin America and Finland, a nonsigni? cant but protective trend was observed against severe disease associated with P[4]G2 (3). Furthermore, in a subsequent meta-analysis, protection against P [4] G2 rotavirus gastroenteritis of any severity was 81% (95% CI 31-96) and protection against severe rotavirus gastroenteritis was 71% (95% CI 20-91) (4) .
To reinforce the hypothesis that predominance of P [4] G2 strains in Aracaju is unrelated to vaccine use, it is worth mentioning that P[4]G2 rotaviruses appear to display an ≈10-year cyclic pattern of occurrence in Brazil (5) . Although the data presented in the original article may cause misinterpretation about vaccine protection, the article highlights the need for well-designed postmarketing studies to assess both vaccine impact and strain surveillance, in compliance with recent World Health Organization recommendations (6). (1) and by Linhares and Velázquez (2) about our article that documented the presence of a single rotavirus genotype (P[4]G2) in Aracaju, northeastern Brazil, after the introduction of a human, monovalent rotavirus vaccine (3). Both letters emphasize that the predominance of P[4]G2 may be caused by a natural genotype variation unrelated to vaccination. We agree that our observation could be explained by natural variation of circulating rotavirus genotypes in the region, but an alternative possibility is that the introduction of the G1P[8] rotavirus vaccine into the childhood immunization schedule created conditions in which P [4] G2 strains had a selective advantage over strains with which the vaccine shares G type, P type, or both.
According to a systematic review of rotavirus genotypes reported in the 25 years preceding introduction of the vaccine in Brazil, the prevalence of P [4] G2 strains varied from 19% (1986-1995) to 12% (1996-2000) to 1% thereafter, thus not reaching the detection rate we observed in Aracaju (R.Q. Gurgel et al., unpub data). Furthermore, in the ensuing 8-month period, no genotype other than P [4] G2 had been detected in Aracaju, suggesting that our initial ? ndings were not spurious (R.Q. Gurgel et al., unpub data). In addition, in a separate study we conducted in Recife, a city 500 km north of Aracaju, we observed a signi? cant increase in the proportion of G2 strains (4) . We believe that our ? ndings are consistent with results of ? eld trials that indicated that the vaccine provided relatively less protection against P [4] G2 strains than against other rotavirus strain types (5).
The bene? cial impact of rotavirus vaccination in northeastern Brazil is re? ected in the reduction of the detection rate of rotavirus among severe diarrhea cases in our study in Recife, which fell from 27% (45/166 cases) to 5.0% (11/221 cases) in the postvaccine 3-month reporting periods, respectively (4). Our data from Aracaju are indicative of heterotypic protection, although this is not statistically signi? cant (1), against P [4] We regret any confusion this error may have caused.
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